• Experienced Leadership Team

• Chairman is the Former CIO Novartis, Biogen, Board member for UMass Memorial Health, Harvard Pilgrim

• Highly capital efficient, founder-owned, funded by management, UHNWI, a prominent Single Family Office and deal revenue

• Based in Oxford, UK, Cambridge (MA), Denmark and Poland, with 32 headcount

• Highly scalable and differentiated platform validated in 40+ disease studies

• Chronic disease focus prioritizing neurological, cardiometabolic, respiratory and autoimmune, generating huge repository of novel IP

• Highly differentiated capabilities with core technology protected using trade secret and patent (US10948887)

• ISO27001 and ISO27701 accredited for data security

PrecisionLife ® Analytics Platform delivers deep insights into chronic diseases (account for 80% of all healthcare costs)

• Pipeline of 250+ precision drug repositioning (INDx indication extension) candidates worth up to £875M+

• Company pipeline includes 300+ novel drug targets all enabled by patient stratification biomarkers

• New second medical use patent application filed on asset potentially addressing ¼ of Alzheimer’s market ($8 Billion per year peak forecast sales potential)

Significant commercial traction proving business model with partnering pipeline of further 40+ qualified opportunities

• Signed partnership with Top 5 pharma company to mine their Phase III clinical trials data for drug response biomarkers and novel targets in CNS disorder

• Signed CNS indication biomarker discovery partnership with milestones with Sosei Heptares for a core program

• Signed major strategic R&D partnership in precision neuroscience with Ono Pharmaceutical